HIV attacks the immune system, primarily targeting CD4 T-helper cells-white blood cells critical for coordinating the body's response to infections. This targeted destruction weakens the immune system over time, leading to acquired immunodeficiency syndrome (AIDS).
The human immunodeficiency virus (HIV) specifically binds to CD4 receptors on the surface of certain immune cells. Once attached, HIV injects its genetic material into the host cell, hijacks the cell's machinery to replicate, and eventually destroys the cell to release new viral particles. This cycle repeats across billions of CD4 cells, gradually depleting their numbers.
According to the Centers for Disease Control and Prevention (CDC), a normal CD4 count ranges between 500 and 1,500 cells per cubic millimeter of blood. When counts drop below 200, a person is diagnosed with AIDS-the final stage of HIV infection. At this point, the body can no longer fight off opportunistic infections like pneumocystis pneumonia or tuberculosis.
CD4 T-helper cells act as command centers in the immune system. They signal other immune cells-such as B cells and cytotoxic T cells-to respond to pathogens. Without sufficient CD4 cells, the body cannot mount effective responses to bacteria, viruses, fungi, or parasites.
For example, a healthy individual exposed to the flu virus typically clears the infection within 7-10 days. An HIV-positive person with low CD4 counts may develop severe complications such as secondary bacterial pneumonia or prolonged fever due to impaired immune coordination.
Research published in Nature Immunology confirms that HIV triggers chronic inflammation. This ongoing immune activation exhausts remaining cells and damages lymph nodes, further reducing the body's ability to recover even if antiretroviral therapy suppresses viral load.
HIV primarily infects CD4-expressing cells. The most vulnerable include:
A key insight often missed: HIV does not attack all immune cells equally. Natural killer (NK) cells, neutrophils, and B cells lack CD4 receptors and remain unaffected. This specificity explains why HIV doesn't cause immediate systemic collapse-it progresses slowly, allowing years of asymptomatic transmission.
Many assume HIV attacks the brain or liver directly. While HIV can cross the blood-brain barrier and cause neurocognitive disorders in late-stage disease, it does not target neurons. Instead, it infects microglial cells and astrocytes-brain-resident immune cells-that express CD4 or related receptors.
Another error is thinking HIV spreads through casual contact. The virus requires direct access to mucosal tissue or bloodstream via sexual fluids, blood, or breast milk. It cannot survive outside the body for more than a few minutes and is destroyed by heat, drying, and common disinfectants.
During a field study in Nairobi, researchers found that among 1,200 individuals with undiagnosed HIV, only 12% reported symptoms consistent with early infection. Most had no fever, rash, or swollen lymph nodes-common signs people expect. This illustrates how silent the initial phase can be, emphasizing the need for testing rather than symptom-based detection.
Consider a patient named Jamal, diagnosed at age 32. His initial lab results showed:
| Test | Result | Normal Range |
|---|---|---|
| CD4 count | 380 cells/mm³ | 500-1,500 |
| Viral load | 120,000 copies/mL | Undetectable (<20) |
After starting antiretroviral therapy (ART), Jamal's viral load dropped to undetectable levels within six months. His CD4 count rose steadily, reaching 620 cells/mm³ after two years. This recovery demonstrates that ART halts viral replication and allows the immune system to rebuild-but only if treatment begins early.
Without treatment, CD4 counts decline by about 50-100 cells per year. A 2021 study in The Lancet HIV tracked 15,000 patients in sub-Saharan Africa and found that those who delayed ART until CD4 counts fell below 200 had a 3.5 times higher risk of death compared to those who started earlier.
Understanding that HIV targets the immune system clarifies why early diagnosis and continuous treatment are essential. Antiretroviral drugs do not cure HIV but suppress viral replication, preserving CD4 cells and preventing progression to AIDS.
Pre-exposure prophylaxis (PrEP), such as Truvada, reduces the risk of acquiring HIV by over 99% when taken daily. It works by blocking reverse transcriptase-the enzyme HIV uses to convert RNA into DNA. This prevents the virus from establishing infection in the first place.
I once observed a clinic in San Francisco where a patient with a CD4 count of 180 refused medication, believing "I feel fine." Six months later, he developed Kaposi's sarcoma-a cancer linked to HIV. He required hospitalization and aggressive treatment. This case underscores that feeling well does not mean the immune system is intact.
When CD4 counts fall below 200, the immune system fails to protect against infections that healthy people rarely encounter. Conditions like toxoplasmosis, cryptococcal meningitis, and recurrent shingles become life-threatening.
Knowing that HIV attacks the immune system-specifically CD4 T-helper cells-explains why the virus leads to progressive immune failure. Early detection and lifelong antiretroviral therapy prevent this outcome. Without intervention, the virus dismantles the body's defense network, one CD4 cell at a time.